1. P-287Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): a randomized, open-label phase 2 study. (21st June 2016) Authors: Andrew, Dean; Ramesh, Ramanathan; Brooke, Belota; Bruce, Belanger; Deyaa, Adib; Eliel, Bayever; Li-Tzong, Chen Journal: Annals of oncology Issue: Volume 27(2016)Supplement 2 Page Start: ii84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗